Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.40946 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Julia-Tatjana Maul und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Psoriasis, Registries, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months’ follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zürich, Zürich, Switzerland.
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Department of Dermatology, University Hospital Basel, Basel, Switzerland.
- Swiss4ward, Alicante, Spain.
- Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Psoriasis Research and Treatment Centre, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berli…
Zitieren
APA
Maul, J. T., Ak, M., Cerminara, S. E., Steinmann, S., Goessinger, E. V., Darzina, A., Oyanguren Monferrer, I., Micheroli, R., Kokolakis, G., Roider, E., Oestereich, F., Mateu, E., Burlando, M., Navarini, A. A., Kündig, T., & Maul, L. V. (2024). Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT). Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.40946
Vancouver
Maul JT, Ak M, Cerminara SE, Steinmann S, Goessinger EV, Darzina A, et al. Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT). Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.40946
BibTeX
@article{Maul2024,
author = {Maul, Julia-Tatjana and Ak, Melike and Cerminara, Sara E and Steinmann, Simona and Goessinger, Elisabeth V and Darzina, Anna and Oyanguren Monferrer, Iker and Micheroli, Raphael and Kokolakis, Georgios and Roider, Elisabeth and Oestereich, Felix and Mateu, Eva and Burlando, Martina and Navarini, Alexander A and Kündig, Thomas and Maul, Lara Valeska},
title = {Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.40946}
}
EUVIMED